CEFOTAXIME (cefotaxime) by Hikma is clinical pharmacology following im administration of a single 500 mg or 1 g dose of cefotaxime to normal volunteers, mean peak serum concentrations of 11. Approved for incidence of certain postoperative infections, development of drug-resistant bacteria, maintain the effectiveness of cefotaxime for injection and 5 more indications. First approved in 2002.
Drug data last refreshed 20h ago
CLINICAL PHARMACOLOGY Following IM administration of a single 500 mg or 1 g dose of cefotaxime to normal volunteers, mean peak serum concentrations of 11.7 and 20.5 mcg/mL respectively were attained within 30 minutes and declined with an elimination half-life of approximately 1 hour. There was a…
Worked on CEFOTAXIME at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.